ERIS Lifesciences Ltd (ERIS) is currently trading at 1,434.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Eris Lifesciences is primarily engaged in manufacturing and marketing pharmaceutical products focused on chronic and acute therapeutic areas like diabetes, cardiology, and gastroenterology. Their operations are specially targeted towards specialists and super-specialists. The company has shown notable revenue growth with a Q2 FY26 revenue increase of 7% year-on-year, reflecting strong performance in the domestic market despite some operational challenges. Eris Lifesciences recently amplified its insulin production capabilities through strategic partnership expansions and intends to double its manufacturing capacity to leverage the growing insulin market opportunities. The company is working on an expansive capex plan aimed at enhancing its manufacturing and market capabilities, with a total estimated outlay of Rs. 380-400 crore over the coming quarters. Strategically, Eris' partnerships, notably with Biocon and Swiss Parenterals, showcase their efforts in enhancing market reach and operational efficiencies, providing a foundation for significant future growth.

Over the past 52 weeks, ERIS Lifesciences Ltd has traded between a low of ₹1,140.00 and a high of ₹1,909.55. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

ERIS Lifesciences Ltd has a market capitalization of approximately 19,838.61. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

ERIS Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 47.77 and operates in the Pharmaceuticals sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

You can buy shares of ERIS Lifesciences Ltd (ERIS) through any SEBI-registered stockbroker in India. A demat and trading account are required to place buy or sell orders on stock exchanges such as NSE or BSE. Shares are credited to the demat account as per the exchange settlement cycle.

Based on its market capitalization of 19,838.61 Cr, ERIS Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

ERIS Lifesciences Ltd operates in the Pharmaceuticals sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of ERIS Lifesciences Ltd is 47.77. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

ERIS Lifesciences Ltd pays dividends with a current dividend yield of 0.50%. Dividend-paying stocks may provide periodic income in addition to potential long-term capital appreciation.

Key risks associated with ERIS Lifesciences Ltd include sector-specific challenges in the Pharmaceuticals industry, regulatory changes, competitive pressures, company-level financial performance, overall market volatility, and broader macroeconomic factors that can impact stock prices.